Studying the Impact of a Medication Use Evaluation by the Community Pharmacist

NCT ID: NCT03179722

Last Updated: 2019-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

453 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-08

Study Completion Date

2018-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this intervention study, 75 Belgian community pharmacies each recruit 12 patients for an intermediate medication review. For each patient, the identified drug-related problems and subsequent interventions are registered using the PharmDisc classification. In a subset of Dutch speaking patients, a pretest-posttest single group design is used to measure the impact of this review on patient related outcomes using questionnaires. The primary outcome is the medication related quality of life, measured via the living with medicines questionnaire. Other patient reported outcomes include adherence, self-management, patient satisfaction, fall incidents and use of emergency healthcare services. Medication records are also collected to objectively measure adherence before and after the intervention.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Parallel group intervention study. In a subset of 140 patients, a pre-post study design is used.
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group: Frenchspeaking patients

Intervention: Medication review

Group Type EXPERIMENTAL

Medication review

Intervention Type BEHAVIORAL

The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

Intervention group: Dutchspeaking patients

Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires

Group Type EXPERIMENTAL

Medication review

Intervention Type BEHAVIORAL

The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

Additional data collection: questionnaires

Intervention Type BEHAVIORAL

Pre-post study design.

At three timepoints, data is collected:

* before the medication review (T-1week)
* during the review (Tweek 3)
* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medication review

The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.

Intervention Type BEHAVIORAL

Additional data collection: questionnaires

Pre-post study design.

At three timepoints, data is collected:

* before the medication review (T-1week)
* during the review (Tweek 3)
* after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medication use review Medication review type 2a Intermediate medication review

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients should be 70 years or older
* Use five or more drugs on a regular basis (prescription or non-prescription drugs)
* Live in the ambulatory setting
* Obtain his medication from this pharmacy on a regular basis

Exclusion Criteria

\-
Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Association of Belgian Pharmacies (APB)

UNKNOWN

Sponsor Role collaborator

Joke Wuyts

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Joke Wuyts

PharmD

Responsibility Role SPONSOR_INVESTIGATOR

References

Explore related publications, articles, or registry entries linked to this study.

Wuyts J, Maesschalck J, De Wulf I, Foubert K, Boussery K, De Lepeleire J, Foulon V. Studying the impact of a medication use evaluation for polymedicated older patients by the community pharmacist (SIMENON): study protocol. BMC Health Serv Res. 2018 Aug 8;18(1):623. doi: 10.1186/s12913-018-3440-z.

Reference Type DERIVED
PMID: 30089523 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://link.springer.com/article/10.1007/s11096-017-0462-2

Protocol Abstract for the PCNE conference 2017 (DOI: 10.1007/s11096-017-0462-2)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SIMENONv3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Polypharmacy Outpatient Clinic
NCT03911934 COMPLETED NA